Welcome back. In my opinion, clinical trials for breast cancer should attract a whole lot of attention. I may not like the company, but I pray for the drug's success.
They could hit a grand slam with this if they get clinicals for prostate cancer.
I was surprized to see the lack of pps gain that we experienced yesterday, I truly thought it would close two to three cents higher than it did.
Market Data 
Markets 
AI
